CD274 and melanoma: In a real-world analysis, Ellebaek et al. demonstrated that PD-L1 expression (threshold defined as >1%, assay clone and platform not specified) was an independent positive prognostic biomarker for melanoma-specific survival in patients receiving ICI therapy (HR = 0.66; 95% CI 0.52–0.83, p < 0.001) [62].